Convalescent plasma transfusion for immunocompromised viremic patients with COVID-19: A retrospective multicenter study.
| dc.rights.license | open | en_US |
| dc.contributor.author | DESTREMAU, Marjolaine | |
| dc.contributor.author | CHAUSSADE, Hélène | |
| dc.contributor.author | HEMAR, Victor | |
| dc.contributor.author | BEGUET, Mathilde | |
| dc.contributor.author | BELLECAVE, Pantxika | |
| dc.contributor.author | BLANCHARD, Elodie | |
| dc.contributor.author | BARRET, Amaury | |
| dc.contributor.author | LABOURE, Gaelle | |
| dc.contributor.author | VASCO-MOYNET, Claire | |
| dc.contributor.author | LACASSIN, Flore | |
| dc.contributor.author | MORISSE, Eloïse | |
| dc.contributor.author | AGUILAR, Claire | |
| dc.contributor.author | LAFARGE, Xavier | |
| dc.contributor.author | LAFON, Marie-Edith | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| hal.structure.identifier | Global Health in the Global South [GHiGS] | |
| dc.contributor.author | BONNET, Fabrice | |
| dc.contributor.author | ISSA, Nahéma | |
| dc.contributor.author | CAMOU, Fabrice | |
| dc.date.accessioned | 2024-09-24T08:17:22Z | |
| dc.date.available | 2024-09-24T08:17:22Z | |
| dc.date.issued | 2024-04-01 | |
| dc.identifier.issn | 1096-9071 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/201762 | |
| dc.description.abstractEn | This study aims to assess the safety, virological, and clinical outcomes of convalescent plasma transfusion (CPT) in immunocompromised patients hospitalized for coronavirus disease 2019 (COVID-19). We conducted a retrospective multicenter cohort study that included all immunosuppressed patients with COVID-19 and RNAemia from May 2020 to March 2023 treated with CPT. We included 81 patients with hematological malignancies (HM), transplants, or autoimmune diseases (69% treated with anti-CD20). Sixty patients (74%) were vaccinated, and 14 had pre-CPT serology >264 BAU/mL. The median delay between symptom onset and CPT was 23 days [13-31]. At D7 post-CPT, plasma PCR was negative in 43/64 patients (67.2%), and serology became positive in 25/30 patients (82%). Post-CPT positive serology was associated with RNAemia negativity (p < 0.001). The overall mortality rate at D28 was 26%, being higher in patients with non-B-cell HM (62%) than with B-cell HM (25%) or with no HM (11%) (p = 0.02). Patients receiving anti-CD20 without chemotherapy had the lowest mortality rate (8%). Positive RNAemia at D7 was associated with mortality at D28 in univariate analysis (HR: 3.05 [1.14-8.19]). Eight patients had adverse events, two of which were severe but transient. Our findings suggest that CPT can abolish RNAemia and ameliorate the clinical course in immunocompromised patients with COVID-19. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | Humans | |
| dc.subject.en | COVID-19 | |
| dc.subject.en | Blood Component Transfusion | |
| dc.subject.en | COVID-19 Serotherapy | |
| dc.subject.en | Cohort Studies | |
| dc.subject.en | Plasma | |
| dc.subject.en | Hematologic Neoplasms | |
| dc.subject.en | Immunocompromised Host | |
| dc.subject.en | Viremia | |
| dc.title.en | Convalescent plasma transfusion for immunocompromised viremic patients with COVID-19: A retrospective multicenter study. | |
| dc.title.alternative | J Med Virol | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1002/jmv.29603 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 38619025 | en_US |
| bordeaux.journal | Journal of Medical Virology | en_US |
| bordeaux.page | e29603 | en_US |
| bordeaux.volume | 96 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 4 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | GHIGS_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Institut de Recherche pour le Développement | en_US |
| bordeaux.import.source | pubmed | |
| hal.identifier | hal-04707122 | |
| hal.version | 1 | |
| hal.date.transferred | 2024-09-24T08:17:27Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| workflow.import.source | pubmed | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Medical%20Virology&rft.date=2024-04-01&rft.volume=96&rft.issue=4&rft.spage=e29603&rft.epage=e29603&rft.eissn=1096-9071&rft.issn=1096-9071&rft.au=DESTREMAU,%20Marjolaine&CHAUSSADE,%20H%C3%A9l%C3%A8ne&HEMAR,%20Victor&BEGUET,%20Mathilde&BELLECAVE,%20Pantxika&rft.genre=article |
